{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:44:43Z","timestamp":1785465883147,"version":"3.56.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.bcmd.2022.102663","type":"journal-article","created":{"date-parts":[[2022,4,12]],"date-time":"2022-04-12T13:51:39Z","timestamp":1649771499000},"page":"102663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study"],"prefix":"10.1016","volume":"95","author":[{"given":"Assaf A.","family":"Barg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Brutman-Barazani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einat","family":"Avishai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Budnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rima","family":"Dardik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Levy-Mendelovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Livnat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2022.102663_bb0005","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcmd.2017.02.003","article-title":"Rare bleeding disorders-old diseases in the era of novel options for therapy","volume":"67","author":"Livnat","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2022.102663_bb0010","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1182\/blood-2018-06-820738","article-title":"Treatment of rare factor deficiencies other than hemophilia","volume":"133","author":"Menegatti","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0015","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1074\/jbc.272.7.4367","article-title":"Regulation of tissue factor initiated thrombingeneration by the stoichiometric inhibitors tissue factor pathway in-hibitor, antithrombin III, and heparin cofactor II","volume":"272","author":"Van't Veer","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2022.102663_bb0020","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1182\/blood-2013-11-512764","article-title":"Biology of tissue factor pathway inhibitor","volume":"123","author":"Wood","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/ATVBAHA.115.305996","article-title":"Tissue factor pathway inhibitor: multiple anticoagulant activities for a single protein","volume":"36","author":"Mast","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.bcmd.2022.102663_bb0030","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/ijlh.13155","article-title":"Investigation of patients with unclassified bleeding disorder and abnormal thrombin generation for physiological coagulation inhibitors reveals multiple abnormalities and a subset of patients with increased tissue factor pathway inhibitor activity","volume":"42","author":"MacDonald","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.bcmd.2022.102663_bb0035","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/bloodadvances.2020003464","article-title":"Elevated levels of tissue factor pathway inhibitor in patients with mild to moderate bleeding tendency","volume":"5","author":"Mehic","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.bcmd.2022.102663_bb0040","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2002-10-3188","article-title":"Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis","volume":"101","author":"Dahm","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3324\/haematol.2019.232132","article-title":"Hemophilia therapy: the future has begun","volume":"105","author":"Mannucci","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bcmd.2022.102663_bb0050","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood.2019002900","article-title":"TFPI blockade: removing coagulation's brakes","volume":"134","author":"Sidonio","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2022.102663_bb0060","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/hae.13627","article-title":"Concizumab restores thrombin generation potential in patients with haemophilia: pharmacokinetic\/pharmacodynamic modelling results of concizumab phase 1\/1b data","volume":"25","author":"Eichler","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcmd.2022.102663_bb0065","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jth.14207","article-title":"A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers","volume":"16","author":"Cardinal","year":"2018","journal-title":"J. Thromb. Haemost."},{"issue":"Suppl 4","key":"10.1016\/j.bcmd.2022.102663_bb0070","first-page":"79","article-title":"PF-06741086, a monoclonal antibody with tissue factor pathway inhibitor (TFPI) neutralizing activity, improves coagulation parameters in global hemostatic assays in hemophilic whole blood and plasma","volume":"22","author":"Hett","year":"2016","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.bcmd.2022.102663_bb0075","first-page":"757","article-title":"Efficacy of anti-TFPI antibody PF-06741086 compared to rFactor VIIa in mouse hemophilia a bleeding models","volume":"22","author":"Jasuja","year":"2017","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2022.102663_bb0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/hae.13820","article-title":"Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas","volume":"25","author":"Patel-Hett","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcmd.2022.102663_bb0085","first-page":"85","article-title":"A phase 1b\/2 study of the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of PF-06741086, an anti-TFPI monoclonal antibody, in patients with severe hemophilia A or B","volume":"3","author":"Mahlangu","year":"2019","journal-title":"Res. Pract. Haemost. Thromb."},{"key":"10.1016\/j.bcmd.2022.102663_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27381","article-title":"Alternative treatment options for pediatric hemophilia B patients with high-responding inhibitors: a thrombin generation-guided study","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcmd.2022.102663_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcmd.2020.102416","article-title":"Thrombin generation in plasma of patients with haemophilia a and B with inhibitors: effects of bypassing agents and antithrombin reduction","volume":"82","author":"Livnat","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2022.102663_bb0100","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bjh.16964","article-title":"Emicizumab treatment and monitoring in a paediatric cohort: real-world data","volume":"191","author":"Barg","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2022.102663_bb0105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00001721-199507000-00004","article-title":"Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A","volume":"6","author":"Erhardtsen","year":"1995","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.bcmd.2022.102663_bb0110","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2008-06-162453","article-title":"Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency","volume":"112","author":"Duckers","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0115","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1055\/s-0033-1349223","article-title":"Combined deficiency of coagulation factors V and VIII: an update","volume":"39","author":"Zheng","year":"2013","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.bcmd.2022.102663_bb0120","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2516.2007.01612.x","article-title":"Congenital FX deficiency combined with other clotting defects or with other abnormalities: a critical evaluation of the literature","volume":"14","author":"Scapin","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcmd.2022.102663_bb0125","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1182\/blood-2002-09-2794","article-title":"Prevalence, causes, and characterization of factor XI inhibitors in patients with inherited factor XI deficiency","volume":"101","author":"Salomon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0130","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1182\/blood-2012-10-462085","article-title":"Alloantibodies in von Willebrand disease","volume":"122","author":"James","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2022.102663_bb0135","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1111\/hae.13620","article-title":"Thromboelastography and thrombin generation assay in inherited afibrinogenemia","volume":"24","author":"Young","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcmd.2022.102663_bb0140","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13049-021-00867-5","article-title":"Normalization of blood clotting characteristics using prothrombin complex concentrate, fibrinogen and FXIII in an albumin based fluid: experimental studies in thromboelastometry","volume":"29","author":"Koller","year":"2021","journal-title":"Scand. J. Trauma Resusc.Emerg. Med."},{"key":"10.1016\/j.bcmd.2022.102663_bb0145","article-title":"Progress in the development of anti-tissue factor pathway inhibitors for haemophilia management","volume":"8","author":"Mahlangu","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"issue":"2021","key":"10.1016\/j.bcmd.2022.102663_bb0150","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/ajh.26018","article-title":"Clinical trials update: innovations in hemophilia therapy","volume":"96","author":"Croteau","year":"2021","journal-title":"Am. J. Hematol."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979622000201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979622000201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:36:10Z","timestamp":1761050170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979622000201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":30,"alternative-id":["S1079979622000201"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2022.102663","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-TFPI for hemostasis induction in patients with rare bleeding disorders, an ex vivo thrombin generation (TG) guided pilot study","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2022.102663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102663"}}